NOR-TEST
(2017)Objective
Tenecteplase vs. alteplase in acute ischemic stroke.
Study Summary
• Tenecteplase is as effective as alteplase with a similar safety profile, potentially offering an alternative in acute stroke thrombolysis..
Intervention
Tenecteplase administered at a dose of 0.4 mg/kg.
Inclusion Criteria
Patients with acute ischemic stroke eligible for thrombolytic therapy within 4.5 hours of symptom onset.
Study Design
Arms: Tenecteplase vs. Alteplase
Patients per Arm: Tenecteplase: 500, Alteplase: 500
Outcome
• In the Tenecteplase arm, 64% of patients achieved functional independence (mRS 0-2) at 90 days with a median mRS score of 2. <br>• The sICH rate was reported at 2.5%. <br>• Comparatively, in the Alteplase arm, 62% achieved functional independence with a median mRS score of 2 and an sICH rate of 2.7%..